Global Automated Analyzers Market By Product Type (Immuno-based Analyzers, Biochemistry Analyzers, and Hematology Analyzers), By Application (Drug Discovery, Genomics, Bioanalysis, Proteomics, and Analytical Chemistry), By End-user (Hospitals & Clinics, Research Institutes, and Others), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Report Overview

The Global Automated Analyzers Market size is expected to be worth around USD 24.7 billion by 2033 from USD 7.8 billion in 2023, growing at a CAGR of 12.2% during the forecast period 2024 to 2033.

Rising demand for automated analyzers is driven by the need for faster, more accurate diagnostics in healthcare, pharmaceuticals, and research laboratories. Automated analyzers streamline processes in clinical testing, blood analysis, and chemical diagnostics, reducing human error and improving efficiency. These devices are increasingly used in applications such as disease detection, drug development, and environmental monitoring.

In February 2021, Yokogawa Electric Co., Ltd. partnered with HIROT SUBIO SCIENCE (HBS) to expand the use of HBS’s N-NOSE cancer screening service, which utilizes nematodes’ olfactory function for early cancer detection. Yokogawa’s investment aims to support the development and maintenance of N-NOSE automated analyzers, showcasing the growing trend of innovation in automated diagnostic tools. Opportunities for growth in this market arise from technological advancements, increased demand for precision diagnostics, and the integration of AI in automated systems.

Key Takeaways

• Market Size: Global Automated Analyzers Market size is expected to be worth around USD 24.7 billion by 2033 from USD 7.8 billion in 2023
• Market Growth: The market growing at a CAGR of 12.2% during the forecast period 2024 to 2033.
• Product Analysis: The immuno-based analyzers segment led in 2023, claiming a market share of 48.3%.
• Application Analysis: The drug discovery held a significant share of 42.4% due to the rising demand for high-throughput screening and precise analysis in pharmaceutical research.
• End-Use Analysis: The hospitals & clinics segment had a tremendous growth rate, with a revenue share of 57.6% in 2023.
• Regional Analysis: North America dominated the market with the highest revenue share of 40.1% in 2023.
• Technological Advancements: Innovations such as AI integration and miniaturization are enhancing the capabilities and reducing the footprint of automated analyzers.
• Healthcare Demand: Increased healthcare requirements, especially due to aging populations and the prevalence of chronic diseases, are boosting the use of automated analyzers.
• Laboratory Efficiency: Automated analyzers significantly improve lab productivity by speeding up the testing process and reducing the potential for human error.

By Product Type Analysis

The immuno-based analyzers segment led in 2023, claiming a market share of 48.3% owing to their increasing use in diagnostic testing and disease monitoring. Immuno-based analyzers are highly effective in detecting antigens and antibodies, making them crucial in the diagnosis of infectious diseases, autoimmune disorders, and cancer.

The growing prevalence of chronic diseases and the rising demand for early and accurate diagnostics are expected to drive the adoption of these analyzers. Technological advancements, such as improved sensitivity and faster processing times, are likely to enhance their utility in clinical laboratories, further propelling the segment’s growth.

By Application Analysis

The drug discovery held a significant share of 42.4% due to the rising demand for high-throughput screening and precise analysis in pharmaceutical research. Automation in drug discovery processes allows for faster identification of potential therapeutic compounds, reducing the time and cost associated with new drug development.

The growing focus on personalized medicine and targeted therapies is expected to increase the use of automated analyzers in identifying biomarkers and understanding drug efficacy. Additionally, the expanding biotechnology sector and increased research investments are likely to further boost the demand for automated analyzers in drug discovery.

By End-user Analysis

The hospitals & clinics segment had a tremendous growth rate, with a revenue share of 57.6% owing to the increasing need for efficient and rapid diagnostic solutions in healthcare settings. The rising incidence of chronic diseases, coupled with growing patient admissions, has led hospitals and clinics to adopt automated analyzers to improve workflow and deliver faster test results.

Automated analyzers help healthcare facilities manage large volumes of diagnostic tests, enhancing operational efficiency and patient care. Additionally, advancements in automation technology that improve accuracy and reduce human error are anticipated to drive the growth of this segment, particularly in large hospitals with high patient throughput.

Key Market Segments

By Product Type

• Immuno-based Analyzers
• Biochemistry Analyzers
• Hematology Analyzers

By Application

• Drug Discovery
• Genomics
• Bioanalysis
• Proteomics
• Analytical Chemistry

By End-user

• Hospitals & Clinics
• Research Institutes
• Others

Drivers

Increasing Government Initiatives

Increasing government initiatives drive the growth of the automated analyzers market by fostering healthcare advancements, particularly in developing regions. For instance, in November 2023, the Republic of Korea donated fully automated biochemistry analyzers worth US$ 402,500 to Nepal. This donation, accepted by Nepal’s Ministry of Health and Population, highlights how governments are prioritizing modernizing medical infrastructure.

These initiatives aim to improve diagnostic capabilities, especially in resource-constrained settings and are anticipated to bolster demand for automated analyzers globally. As more governments invest in healthcare technologies, the market is projected to grow, enabling better and faster diagnostic outcomes in clinical laboratories.

Restraints

Rising Regulatory Frameworks

Rising regulatory frameworks hamper the growth of the automated analyzers market by prolonging the time and costs associated with product approval. For instance, the U.S. Food and Drug Administration (FDA) requires devices used for in-vitro diagnostic purposes to undergo a rigorous premarket approval process.

This process includes clinical trials and extensive documentation, often taking 2-3 years to complete. Such stringent regulations impede manufacturers from quickly launching new products, delaying their entry into the market. The complex and time-consuming nature of these regulatory requirements is projected to restrain market growth, particularly for smaller companies with limited resources to navigate these regulatory hurdles.

Opportunities

Rising Technological Advancements

Rising technological advancements present a significant opportunity for the automated analyzers market, enabling laboratories to improve efficiency and diagnostic accuracy. In April 2021, Roche introduced Cobas Pure Integrated Solutions, a compact analyzer that combines three technologies into a single platform, catering to labs with limited space and resources.

This innovation simplifies daily operations by reducing the need for multiple devices, thereby enhancing workflow efficiency. As demand for integrated and space-saving solutions grows, technological advancements like this are projected to expand market opportunities, driving the adoption of next-generation automated analyzers across a wide range of healthcare settings.

Impact of Macroeconomic / Geopolitical Factors

Macroeconomic and geopolitical factors play a significant role in shaping the automated analyzers market, creating both challenges and opportunities. Economic downturns in key regions may reduce healthcare budgets, affecting the adoption of advanced diagnostic technologies. Geopolitical tensions, such as trade restrictions and disruptions in the global supply chain, may increase production costs and delay the delivery of critical components.

On the positive side, rising healthcare investments in emerging markets and government initiatives to improve diagnostic infrastructure drive demand for automation in laboratories. Despite potential disruptions, advancements in healthcare technology and increased focus on precision diagnostics present promising growth opportunities for the market.

Latest Trends

Surge in Production Expansion

Increasing production expansion is driving the automated analyzers market, as companies invest in scaling their manufacturing capabilities to meet growing demand. In January 2024, Beckman Coulter Diagnostics announced plans to introduce the DxC 500 AU Chemistry Analyzer, a next-generation automated clinical chemistry system, at the Medlab Middle East event in Dubai.

This product launch is anticipated to enhance the company’s global presence and support market growth. Growing investments in production facilities and technological innovations are projected to improve product availability and cater to the rising demand for accurate, high-throughput diagnostic solutions, further accelerating the market’s expansion.

Regional Analysis

North America is leading the Automated Analyzers Market

North America dominated the market with the highest revenue share of 40.1% owing to the increasing demand for efficient and accurate diagnostic solutions across healthcare settings. Factors such as the rising prevalence of chronic diseases, advancements in technology, and the need for rapid test results have all contributed to this upward trend. Regulatory approvals of innovative products further bolster the market; for instance, in July 2023, Beckman Coulter, Inc. received U.S. Food and Drug Administration clearance for its new DxC 500 AU Chemistry Analyzer.

This analyzer’s advanced automation reflects a commitment to enhancing product innovation within the in vitro diagnostic sector, thereby improving laboratory productivity and patient outcomes. Additionally, the expansion of laboratory networks and an emphasis on personalized medicine have prompted healthcare providers to adopt automated systems that facilitate higher throughput and reduce human error. Overall, these dynamics position the North American market for continued expansion as healthcare evolves.

The Asia Pacific region is expected to experience the highest CAGR during the forecast period

Asia Pacific is expected to grow with the fastest CAGR owing to rising healthcare investments and increasing laboratory capabilities. Countries such as India, China, and Japan are expected to play pivotal roles in this growth, supported by expanding healthcare infrastructure and heightened demand for efficient diagnostic solutions. On January 4, 2024, HORIBA, Ltd. launched its 2.0 high throughput automated hematology system, which offers a flexible and scalable solution for mid to large-scale laboratories.

This innovation is likely to enhance the operational efficiency of laboratories and cater to the growing demand for hematological testing. As healthcare providers increasingly prioritize speed and accuracy in diagnostics, the adoption of automated analyzers is anticipated to accelerate. The combination of technological advancements, an increasing focus on personalized healthcare, and the need for cost-effective solutions will further drive the growth of this market across the Asia Pacific region.

Key Regions and Countries

North America

• US
• Canada

Europe

• Germany
• France
• The UK
• Spain
• Italy
• Russia
• Netherland
• Rest of Europe

Asia Pacific

• China
• Japan
• South Korea
• India
• Australia
• New Zealand
• Singapore
• Thailand
• Vietnam
• Rest of APAC

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• South Africa
• Saudi Arabia
• UAE
• Rest of MEA

Key Players Analysis

The major players in the automated analyzers market are actively engaged in the development and introduction of innovative products, as well as implementing strategic initiatives aimed at enhancing their competitive positioning. Key players in the automated analyzers market focus on developing high-performance systems that offer faster and more accurate results to meet the demands of modern laboratories.

They collaborate with hospitals and diagnostic centers to integrate their solutions seamlessly into clinical workflows. Companies invest in research and development to innovate with AI-powered features that enhance operational efficiency. Strategic alliances with distributors help expand their global reach and improve product accessibility. Additionally, they target emerging markets with a growing need for advanced diagnostic tools, driving market growth.

Top Key Players

• Trivitron Healthcare
• Thermo Fisher Scientific
• Synchron Lab Automation
• Siemens Healthineers AG
• Qmicro
• Hudson Robotics Inc.
• Danaher Corporation
• CANON MEDICAL SYSTEMS CORPORATION
• Becton Dickinson
• Agilent Technologies Inc.

Recent Developments

• In November 2023, CANON MEDICAL SYSTEMS CORPORATION celebrated the domestic production of its TBA-FX8 fully automated biochemistry analyzer at its Dalian plant in China. Equipped with V2.0 software, the TBA-FX8 enables automatic quality control of multiple reagents simultaneously and provides early warnings for abnormal reaction curves. This development is significant for the growth of the automated analyzers market as it enhances the speed and accuracy of diagnostics, improving laboratory efficiency and reliability.
• In June 2021, Trivitron Healthcare launched two new products, NANO H5 and NANO H110, for high-performance HbA1c and Hb variant detection using liquid chromatography analyzers. These devices deliver results in less than 3 minutes, supporting the growth of the automated analyzers market by improving the speed and precision of diagnostics in diabetes and hemoglobin variant detection.
• In February 2021, Sensirion Holding AG completed the acquisition of Qmicro, an innovative OEM supplier specializing in miniaturized gas-analysis technologies. This acquisition is relevant to the growth of the automated analyzers market as it allows Sensirion to expand its offerings from components to stand-alone micro gas analyzers, meeting the growing demand for automated industrial gas sensing solutions.

Report Scope